NKX2-8

Across TCGA pan-cancer cohorts, NKX2-8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NKX2-8 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NKX2-8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NKX2-8 expression acts as an unfavorable survival marker.

STAD, SKCM, and LIHC are the cancer types where NKX2-8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.184	0.710	.001	15	view →
SKCM	DFS	Median	All	0.209	0.728	.020	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NKX2-8–STAD (OS)

Open the STAD breakdown →